Sublingual immunotherapy for treating adult patients with allergic rhinitis induced by house dust mite among Chinese Han population

A retrospective study

Miao Han, MM*, Yan Chen, MM, Mi Wang, MM

Abstract
The objective of this retrospective study was to evaluate the efficacy and safety of sublingual immunotherapy (SLIT) for treating adult patients with allergic rhinitis (AR) induced by house dust mite (HDM) among Chinese Han population.

A total of 201 adult patients with AR induced by HDM were included. All of them received SLIT treatment. The outcomes consisted of AR symptoms, and quality of life. In addition, any adverse events were also recorded in this study.

Compared with the AR symptoms and quality of life before the treatment, significant differences were found after 1-year treatment ($P < .01$), and 2-year treatment ($P < .01$). Additionally, only mild and acceptable adverse events were observed in this study.

This study demonstrated that SLIT may be efficacious and safe for adult patients with HDM induced by AR among Chinese Han population.

Abbreviations: AR = allergic rhinitis, HDM = house dust mite, RQLQ = Rhinoconjunctivitis Quality of Life Questionnaire, SLIT = sublingual immunotherapy.

Keywords: allergic rhinitis, sublingual immunotherapy, house dust mite, efficacy, safety

1. Instruction

Allergic rhinitis (AR) is one of the most common health problems that affect more than one-third population all around the world.[1,2] In China, it has been reported that its prevalence varies from 9.6% to 23.9%.[3] Previous studies also reported that the house dust mite (HDM) is the most probable inhalant allergen, and cause to the AR.[4–7] Moreover, patients with such condition can also lead to chronic or more severe AR or even asthma when they are exposed to the HDM for long time.[8–10] Additionally, the symptoms of AR are often associated with poor quality of life, sleep disorder, and even emotional issues.[11,12]

The treatment for this condition is costly and imposes a large amount of economic burdens for individuals, families, and the society.[13,14] Most treatments still focus on the symptoms relief for patients with AR, and often suffer from efficacy limitation for long time. Fortunately, more promising treatment of allergen immunotherapy is used as a guideline-recommended treatment for patients with AR.[15–18] It has been reported that this kind of therapy can not only manage the transform of AR to severer condition, but also can prevent AR to develop into asthma with the early treatment.[19,20]

Although sublingual immunotherapy (SLIT) is used to treat AR effectively under the recommendation of the World Allergy Organization,[21] limited data of SLIT for the treatment of AR among adult Chinese Han population has been reported. In this study, we retrospectively analyzed the efficacy and safety of SLIT in patients with AR induced by HDM among Chinese Han adult population specifically.

2. Patients and materials

2.1. Design

This study was approved by the Medical Ethical Committee of Affiliated Hospital of Yan’an University. All patients provided the written informed consent. It was conducted at Affiliated Hospital of Yan’an University between January 2011 and December 2016. All patients received SLIT drops for a total of 2 years. All the outcomes were measured after 1-year, and 2-year treatment.

2.2. Patients

In this retrospective study, 201 adult patients with the diagnosis of persistent AR induced by HDM were included. The moderate-to-severe HDM-induced AR was confirmed diagnosed according to the criteria of diagnosis and the classification of the Allergic Rhinitis and its Impact on Asthma guidelines.[22] It specifically defined as an AR symptom score $\geq 7$, and patients experienced for periods longer than 4d/wk and for $>4$ consecutive weeks. Additionally, inclusion criteria also included patients’
agases >18 years. Furthermore, all patients had moderate to severe persistent AR for at least 1 year with positive nasal provocation test result, and a positive serum HDM-specific IgE level of 3.5 kU/L, according to the *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*.

Exclusion criteria consisted of patients with any kinds of asthma or history of asthma; systemic immunologic disorders; allergic to food, atopic dermatitis, or animal hairs; a specific IgE level of >250 kU/L for any other allergic reasons, such as cedar, muwort, and so on; a history of chronic rhinosinusitis, anaphylactic shock; pregnancy; psychological, or neurological diseases that may affect the outcome assessments; and previously treated with SLIT, β-blockers, or corticosteroids 6 months before the study.

### 2.3. Treatment schedule

SLIT was conducted with standard extract of drops for SLIT (D farinae drops; Wolwopharma Biotechnology, Zhejiang, China) as sublingual drops, according to the schedules, recommended by the manufacturer. All patients received 1 drop of SLIT (333 μ g/mL) once daily within the first month, then added to 2 drops of SLIT (1000 μg/mL) once daily for a total of 2 years. All adverse events were recorded during the period of treatment.

### 2.4. Outcome measurements

The outcomes included AR symptoms, and quality of life, as measured by Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). AR symptoms consists of 6 allergic symptoms, and 4 rhinitis symptoms, with each item scale ranging from 0 (no symptoms) to 3 (severe symptoms). RQLQ includes 28 items, and distributed in 7 domains. Each item presents as a 7-point scale (0 to 6). Higher score indicates poor quality of life. The minimal clinically important difference for the change of each item and overall quality of life is 0.5.[24] Additionally, the safety was also recorded during the period of treatment. All the patients were asked to visit the clinical investigators to conduct all the outcome measurements within 1 month after 1-year, and 2-year treatment, respectively. All the outcome measurements were assessed before the study, and after 1-year, and 2-year treatment.

#### 2.5. Statistical analysis

All data were analyzed by using IBM SPSS Statistics 19.0 (IBM Corp., Armonk, NY). One-sample Kolmogorov–Smirnov test was used to check the distributions of the samples. Quantitative data were analyzed by paired samples *t* test. The statistical significance was defined as *P* < .05.

### 3. Results

The characteristics of all eligible patients are summarized in Table 1. Patients aged from 20 to 49 years, with mean age of 35.7 years. Of them, 138 (68.7%) patients are men. The mean duration of the HDM-induced AR were 11.4 years. Fourteen patients (7.0%) were moderate persistent AR, and 187 (93.0%) patients were severe persistent AR.

The outcome data of symptoms scores are presented in Table 2. When compared with the symptom scores before treatment, significant differences of all symptoms scores were found after 1-year (*P* < .01) and 2-year treatment (*P* < .01). The scores of quality of life are showed in Table 3. After 1-year treatment, the SLIT showed promising enhancement in quality of life, compared with those before the treatment (*P* < .01). This promising trend contributed throughout to the end of 2-year treatment (*P* < .01).

The adverse events related treatment is listed in Table 4. No severe adverse events were recorded during the treatment period. The mainly adverse events were local symptom, gastrointestinal reactions, and aggravation of AR symptom, fever, eye swelling, and skin rash.

### 4. Discussion

Previous studies have explored the efficacy and safety of SLIT for the treatment of adults with AR induced by HDM.[27–34] Four trials focused on the Korea adult population and found that SLIT significantly improved the symptoms and medication scores in patients with AR induced by HDM.[27–30] One retrospective study conducted in Italy and evaluated whether SLIT exerts a long-lasting effect and the association to its duration. The results

### Table 1

| Characteristics | Value |
|-----------------|-------|
| Age, y          | Mean 35.7 (6.8) |
| Range           | 20–49 |
| Gender          | Male 138 (68.7) |
|                | Female 63 (31.3) |
| Ethnicity (Asian Chinese) | 201 (100.0) |
| HDM-induced AR duration, y | 11.4 (5.9) |
| Type of AR      | Moderate persistent 14 (7.0) |
|                | Severe persistent 187 (93.0) |

Note: *Data are present as mean ± standard deviation or number (%). AR=allergic rhinitis, HDM=house dust mite.*

### Table 2

| Symptoms of all included patients between pretreatment and posttreatment. |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Outcome measurements        | Before                      | After 1-year treatment       | *P* value                   | After 2-year treatment       | *P* value                   |
| Runny nose                  | 2.23 (0.41)                 | 1.58 (0.55)                 | <.01                        | 1.02 (0.48)                 | <.01                        |
| Blocked nose                | 2.05 (0.52)                 | 1.39 (0.63)                 | <.01                        | 0.89 (0.44)                 | <.01                        |
| Sneezing                    | 2.10 (0.45)                 | 1.46 (0.54)                 | <.01                        | 0.98 (0.51)                 | <.01                        |
| Itchy nose                  | 2.11 (0.47)                 | 1.40 (0.52)                 | <.01                        | 1.05 (0.47)                 | <.01                        |
| Gritty feeling/red/itchy eyes | 1.52 (0.69)             | 0.84 (0.71)                 | <.01                        | 0.57 (0.49)                 | <.01                        |
| Watery eyes                 | 2.75 (0.74)                 | 0.62 (0.56)                 | <.01                        | 0.36 (0.33)                 | <.01                        |

Note: *Data are present as mean ± standard deviation.*
showed that after 4 years SLIT treatment, the symptoms and bronchial reactivity significantly improved, and even last 7 to 8 years after the treatment.\(^\text{[31]}\) The other trial performed in France, and assessed the efficacy and safety of SLIT in patients with chronic AR related to sensitization to HDM.\(^\text{[32]}\) It is found that SLIT can both improve efficacy criteria, measured by rhinitis score and objective criteria, measured by skin reactivity.\(^\text{[33]}\) Another 2 trials conducted in Japan and Bulgaria to assess the SLIT for treating patients with HDM induced-AR. The results also showed that SLIT can enhance both symptoms and quality of their life in patients with such condition.\(^\text{[33,34]}\) However, no studies specifically focused on exploring the efficacy and safety of SLIT in patients with AR induced by HDM among Chinese Han adult population specifically.

The results of this study are consistent with the previous studies.\(^\text{[27–34]}\) Our study found that the efficacy of SLIT in patients with AR induced by HDM among Chinese Han population is promising with acceptable adverse events. It can not only relieve the symptoms of AR, but also can improve the quality of life in patients with HDM induced by AR.

There are 3 limitations in this retrospective study. First, this study did not consist of a control group for the treatment of SLIT in patients with AR induced by HDM. Second, the other concomitant diseases may affect the outcome assessments of quality of life. Third, this study only included Chinese Han population, which might affect our results generalized to other population. Fourth, this study did not involve the blind procedure to the patients and investigators because of the retrospective study, which may increase the risk of selection.

5. Conclusion

The results of this retrospective study demonstrated that SLIT may be effective in adult patients with AR induced by HDM among Chinese Han population.

### Table 3
Quality of life of all included patients between pretreatment and posttreatment.

| Outcome measurements       | Before         | After 1-year treatment | P value | After 2-year treatment | P value |
|----------------------------|----------------|------------------------|---------|------------------------|---------|
| Activities                 | 3.55 (1.47)    | 2.61 (1.55)            | <.01    | 1.26 (1.17)            | <.01    |
| Sleep                      | 2.51 (1.82)    | 1.58 (1.73)            | <.01    | 0.94 (1.01)            | <.01    |
| General problems           | 1.80 (1.58)    | 1.12 (1.26)            | <.01    | 0.77 (0.86)            | <.01    |
| Practical problems         | 3.61 (1.70)    | 2.49 (1.82)            | <.01    | 1.31 (1.28)            | <.01    |
| Nasal symptoms             | 3.93 (1.67)    | 2.55 (1.71)            | <.01    | 1.36 (1.12)            | <.01    |
| Eye symptoms               | 2.95 (1.84)    | 2.01 (1.78)            | <.01    | 0.92 (0.69)            | <.01    |
| Emotions                   | 3.07 (1.46)    | 1.90 (1.54)            | <.01    | 1.02 (0.83)            | <.01    |
| Overall quality of life    | 2.97 (1.53)    | 1.88 (1.59)            | <.01    | 1.20 (0.79)            | <.01    |

Note: Data are present as mean±standard deviation.

### Table 4
Adverse events related to the treatment.

| Adverse events           | After 1-year treatment | After 2-year treatment |
|--------------------------|------------------------|------------------------|
| Local symptom            | 6 (2.9)                | 21 (10.4)              |
| Gastrointestinal reactions| 2 (1.0)                | 5 (2.5)                |
| Aggravation of AR symptom| 3 (1.5)                | 9 (4.5)                |
| Fever                    | 2 (1.0)                | 4 (2.0)                |
| Eye swelling              | 1 (0.5)                | 3 (1.5)                |
| Skin rash                | 2 (1.0)                | 5 (2.5)                |

Note: Data are present as number (%); AR = allergic rhinitis.

Author contributions

Conceptualization: Miao Han, Yan Chen, Mi Wang. Data curation: Miao Han, Yan Chen, Mi Wang. Formal analysis: Yan Chen. Investigation: Mi Wang. Methodology: Miao Han, Yan Chen. Project administration: Miao Han. Resources: Miao Han, Mi Wang. Software: Yan Chen. Supervision: Miao Han, Mi Wang. Validation: Mi Wang. Visualization: Mi Wang. Writing – original draft: Miao Han, Yan Chen, Mi Wang. Writing – review and editing: Miao Han, Yan Chen, Mi Wang.

References

1. Pawankar R, Sánchez-Borges M, Bonini S, et al. The burden of allergic diseases. In: WAO White Book on Allergy; 2013: 27–33.
2. Salo PM, Calatroni A, Gergen PJ, et al. Allergy-related outcomes in relation to serum IgE: results from the National Health and Nutrition Examination Survey 2005–2006. J Allergy Clin Immunol 2011;127:1226–35.
3. Wang XD, Zheng M, Lou HF, et al. An increased prevalence of self-reported allergic rhinitis in major Chinese cities from 2005 to 2011. Allergy 2016;71:1170–80.
4. Kim DH, Kim SW, Kim SW, et al. Interleukin-37 relieves allergic inflammation in a house dust mite allergic rhinitis murine model. Iran J Allergy Asthma Immunol 2017;16:404–17.
5. Sahin E, Dzidar D, Dinc ME, et al. Long-term effects of allergen-specific subcutaneous immunotherapy for house dust mite induced allergic rhinitis. J Laryngol Otol 2017;131:997–1001.
6. Leger D, Bonnefoy B, Pigeartis B, et al. Poor sleep is highly associated with house dust mite allergic rhinitis in adults and children. Allergy Asthma Clin Immunol 2017;13:36.
7. Feng B, Xiang H, Jin H, et al. Efficacy of sublingual immunotherapy for house dust mite-induced allergic rhinitis: a meta-analysis of randomized controlled trials. Allergy Asthma Immunol Res 2017;9:220–8.
8. Fujisawa T, Shimoda T, Masuyama K, et al. Long-term safety of subcutaneous immunotherapy with TO-204 in Japanese patients with house dust mite-induced allergic rhinitis and allergic bronchial asthma: Multicenter, open label clinical trial. Allergol Int 2018;67:347–56.
9. Richgels PK, Yamami A, Choung CA, et al. Maternal house dust mite exposure during pregnancy enhances severity of house dust mite-induced asthma in murine offspring. J Allergy Clin Immunol 2017;140:1404.e9–15.e9.
10. Shima K, Koya T, Tsukita K, et al. Effects of sublingual immunotherapy in a murine asthma model sensitized by intranasal administration of house dust mite extracts. Allergol Int 2017;66:89–96.
11. Bazarini I, Brando F, Brandi S, et al. Allergic diseases and their impact on quality of life. Ann Allergy Asthma Immunol 2006;97:419–28.
12. Bousquet J, Neukirch F, Bousquet PJ, et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol 2006;117:158–62.
[13] Meltzer EO, Bukstein DA. The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol 2011;106:S12–6.

[14] Yoo KH, Ahn HR, Park JK, et al. Burden of respiratory disease in Korea: an observational study on allergic rhinitis, asthma, COPD, and rhinosinusitis. Allergy Asthma Immunol Res 2016;8:327–34.

[15] Bao Y, Chen J, Cheng L, et al. Chinese Guideline on allergen immunotherapy for allergic rhinitis. J Thorac Dis 2017;9:4607–50.

[16] Lee JH, Kim SC, Choi H, et al. A retrospective study of clinical response predictors in subcutaneous allergen immunotherapy with house dust mites for allergic rhinitis. Allergy Asthma Immunol Res 2018;10:18–24.

[17] Sohn MH. Efficacy and safety of subcutaneous allergen immunotherapy for allergic rhinitis. Allergy Asthma Immunol Res 2018;10:1–3.

[18] Klimek L, Pfärr O, Bousquet J, et al. Allergen immunotherapy in allergic rhinitis: current use and future trends. Expert Rev Clin Immunol 2017;13:897–906.

[19] Morjaria JB, Caruso M, Rosalia E, et al. Preventing progression of allergic rhinitis to asthma. Curr Allergy Asthma Rep 2014;14:412.

[20] Dong X, Huang N, Li W, et al. Systemic reactions to dust mite subcutaneous immunotherapy: a 3-year follow-up study. Allergy Asthma Immunol Res 2016;8:421–7.

[21] Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: world allergy organization position paper 2009. Allergy 2009;64 (suppl):1–59.

[22] Bousquet J, Khalel N, Cruz AA, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63:8–160.

[23] Wang Z, Li W, Chen H, et al. Effect of sublingual immunotherapy on level of cytokines in PBMCs of patients with allergic asthma. J Huazhong Univ Sci Technol Med Sci 2011;31:376–8.

[24] European Medicines Agency. Guideline on the Clinical Development of Products for Specific Immunotherapy for the Treatment of Allergic Diseases. London: European Medicines Agency; 2008. Doc. Ref: CHMP/EWP/18504/2006.

[25] Juniper E, Guyatt G. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991;21:77–83.

[26] Juniper E, Guyatt G, Dolovich J. Assessment of quality of life in children with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol 1989;93:413–22.

[27] Kim SH, Mun SJ, Han DH, et al. Three-year follow-up results of sublingual immunotherapy in patients with allergic rhinitis sensitized to house dust mites. Allergy Asthma Immunol Res 2015;7:118–23.

[28] Kim ST. Outcome of sublingual immunotherapy in patients with allergic rhinitis sensitive to house dust mites. Allergy Asthma Immunol Res 2015;7:99–100.

[29] Kim ST, Han DH, Moon JJ, et al. Clinical and immunologic effects of sublingual immunotherapy on patients with allergic rhinitis to house dust mites: 1 year follow-up results. Am J Rhinol Allergy 2010;24:271–5.

[30] Chang H, Han DH, Mo JH, et al. Early compliance and efficacy of sublingual immunotherapy in patients with allergic rhinitis for house dust mites. Clin Exp Otorhinolaryngol 2009;2:136–40.

[31] Marogna M, Bruno M, Massolo A, et al. Long-lasting effects of sublingual immunotherapy for house dust mites in allergic rhinitis with bronchial hyperreactivity: a long-term (13-year) retrospective study in real life. Int Arch Allergy Immunol 2007;142:70–8.

[32] Tonnel AB, Scherpereel A, Douay B, et al. Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy 2004;59:491–7.

[33] Okubo K, Masuyama K, Imai T, et al. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis. J Allergy Clin Immunol 2017;139:1840–8.

[34] Novakova SM, Staevska MT, Novakova PI, et al. Quality of life improvement after a three-year course of sublingual immunotherapy in patients with house dust mite and grass pollen induced allergic rhinitis: results from real-life. Health Qual Life Outcomes 2017;15:189.